Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer

Toshiyoshi Fujiwara, Noriaki Tanaka, Susumu Kanazawa, Shoichiro Ohtani, Yasuo Saijo, Toshihiro Nukiwa, Kunihiko Yoshimura, Tetsuo Sato, Yoshikatsu Eto, Sunil Chada, Haruhiko Nakamura, Harubumi Kato

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: To determine the feasibility, safety, humoral immune response, and biologic activity of multiple intratumoral injections of Ad5CMV-p53, and to characterize the pharmacokinetics of Ad5CMV-p53 in patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Fifteen patients with histologically confirmed NSCLC and p53 mutations were enrolled onto this phase I trial. Nine patients received escalating dose levels of Ad5CMV-p53 (1 × 109 to 1 × 1011 plaque-forming units) as monotherapy once every 4 weeks. Six patients were treated on a 28-day schedule with Ad5CMV-p53 in combination with intravenous administration of cisplatin (80 mg/m2). Patients were monitored for toxicity, vector distribution, antibody formation, and tumor response. Results: Fifteen patients received a total of 63 intratumoral injections of Ad5CMV-p53 without dose-limiting toxicity. The most common treatment-related toxicity was a transient fever. Specific p53 transgene expression was detected using reverse-transcriptase polymerase chain reaction in biopsied tumor tissues throughout the period of treatment despite of the presence of neutralizing antiadenovirus antibody. Distribution studies revealed that the vector was detected in the gargle and plasma, but rarely in the urine. Thirteen of 15 patients were assessable for efficacy; one patient had a partial response (squamous cell carcinoma at the carina), 10 patients had stable disease, with three lasting at least 9 months, and two patients had progressive disease. Conclusion: Multiple courses of intratumoral Ad5CMV-p53 injection alone or in combination with intravenous administration of cisplatin were feasible and well tolerated in advanced NSCLC patients, and appeared to provide clinical benefit.

Original languageEnglish
Pages (from-to)1689-1699
Number of pages11
JournalJournal of Clinical Oncology
Volume24
Issue number11
DOIs
Publication statusPublished - Apr 10 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Fujiwara, T., Tanaka, N., Kanazawa, S., Ohtani, S., Saijo, Y., Nukiwa, T., Yoshimura, K., Sato, T., Eto, Y., Chada, S., Nakamura, H., & Kato, H. (2006). Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 24(11), 1689-1699. https://doi.org/10.1200/JCO.2005.03.4116